Clinical Trial Update: CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

This document provides a Phase 2 update on a recruiting trial evaluating CPX-351 plus Ivosidenib for IDH1-mutated acute myeloid leukemia and high-risk myelodysp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Ivosidenib (ivosidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome | Phase 2 | Status: RECRUITING